Oncology Financial Statements From 2010 to 2025

TOI Stock  USD 3.73  0.06  1.63%   
Oncology Institute's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Oncology Institute's valuation are provided below:
Gross Profit
59.3 M
Profit Margin
(0.16)
Market Capitalization
337.3 M
Enterprise Value Revenue
0.9965
Revenue
403.2 M
We have found one hundred twenty available trending fundamental ratios for Oncology Institute, which can be analyzed and compared to other ratios and to its competitors. Traders should compare all of Oncology Institute recent fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 22 M. Enterprise Value is estimated to decrease to about 91.8 M

Oncology Institute Total Revenue

256.02 Million

Check Oncology Institute financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncology Institute's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 4.3 M or Interest Expense of 7.9 M, as well as many indicators such as Price To Sales Ratio of 0.056, Dividend Yield of 0.0105 or PTB Ratio of 9.86. Oncology financial statements analysis is a perfect complement when working with Oncology Institute Valuation or Volatility modules.
  
Build AI portfolio with Oncology Stock
Check out the analysis of Oncology Institute Correlation against competitors.
For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.

Oncology Institute Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding76 M75 M67.2 M
Slightly volatile
Total Assets178.6 M172.7 M105.5 M
Slightly volatile
Other Current Liabilities12.2 M16.4 M7.3 M
Slightly volatile
Total Current Liabilities34.6 M52.2 M21.6 M
Slightly volatile
Total Stockholder Equity3.4 M3.6 M46.4 M
Very volatile
Other Liabilities6.7 MM8.4 M
Pretty Stable
Property Plant And Equipment Net21.7 M37.7 M9.6 M
Slightly volatile
Accounts Payable15.6 M24.3 M11.3 M
Slightly volatile
Cash40.3 M49.7 M17.6 M
Slightly volatile
Non Current Assets Total70.1 M60.3 M49.5 M
Slightly volatile
Non Currrent Assets Other377.6 K589 K207.3 K
Slightly volatile
Other Assets279.8 K548.5 K200.2 K
Slightly volatile
Cash And Short Term Investments60.3 M49.7 M25.7 M
Slightly volatile
Net Receivables34 M48.7 M22 M
Slightly volatile
Good Will12.4 M6.5 M14.4 M
Very volatile
Liabilities And Stockholders Equity178.6 M172.7 M105.5 M
Slightly volatile
Non Current Liabilities Total78.1 M116.9 M33.6 M
Slightly volatile
Inventory8.7 M10 M5.7 M
Slightly volatile
Other Current Assets5.5 MM2.6 M
Slightly volatile
Other Stockholder Equity156.1 M214.4 M63 M
Slightly volatile
Total Liabilities112.7 M169.1 M55.2 M
Slightly volatile
Property Plant And Equipment Gross24.5 M44.6 M11 M
Slightly volatile
Total Current Assets108.5 M112.4 M56 M
Slightly volatile
Capital Stock6.8 K7.2 K35.1 M
Slightly volatile
Non Current Liabilities Other118.8 K125 K2.2 M
Pretty Stable
Net Working Capital73.9 M60.2 M34.4 M
Slightly volatile
Intangible Assets14.7 M14.8 M20.2 M
Slightly volatile
Common Stock6.7 K9.2 K3.1 K
Slightly volatile
Property Plant Equipment10.3 M9.8 M3.7 M
Slightly volatile
Short and Long Term Debt Total79.9 M123.2 M35.1 M
Slightly volatile
Current Deferred Revenue4.9 M4.7 M3.1 M
Pretty Stable
Long Term Debt73.5 M93.1 M30.4 M
Slightly volatile
Short and Long Term Debt156.5 K164.7 K3.7 M
Slightly volatile
Short Term Debt5.3 M6.8 M5.2 M
Very volatile
Warrants368 M414 M451.4 M
Slightly volatile
Common Stock Total Equity4.2 K8.1 K2.1 K
Slightly volatile
Capital Surpluse194.5 M214.2 M174.4 M
Slightly volatile

Oncology Institute Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4.3 M6.3 M2.5 M
Slightly volatile
Interest Expense7.9 M7.5 M1.7 M
Slightly volatile
Selling General Administrative61.9 M107.8 M38.7 M
Slightly volatile
Total Revenue256 M393.4 M174.4 M
Slightly volatile
Gross Profit47.1 M54 M34.8 M
Slightly volatile
Other Operating Expenses297 M453.5 M190.9 M
Slightly volatile
Cost Of Revenue208.9 M339.4 M139.6 M
Slightly volatile
Total Operating Expenses88.1 M114.1 M51.3 M
Slightly volatile
Reconciled Depreciation4.2 M6.3 M2.5 M
Slightly volatile
Selling And Marketing Expenses33.3 M37.4 M40.8 M
Slightly volatile

Oncology Institute Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow26.9 M33.5 M12.4 M
Slightly volatile
Depreciation4.3 M6.3 M2.5 M
Slightly volatile
Capital Expenditures3.1 M3.8 M1.8 M
Slightly volatile
End Period Cash Flow34.7 M49.7 M16 M
Slightly volatile
Stock Based Compensation14.9 M11.2 M6.1 M
Slightly volatile
Cash Flows Other Operating6.9 M6.6 M1.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.0560.05893.8364
Slightly volatile
Dividend Yield0.01050.01180.0129
Slightly volatile
PTB Ratio9.866.46112.3062
Slightly volatile
Days Sales Outstanding34.4445.165337.7638
Slightly volatile
Book Value Per Share0.04540.04780.6987
Very volatile
Average Payables8.6 M9.7 M10.6 M
Slightly volatile
Stock Based Compensation To Revenue0.0420.02830.0227
Slightly volatile
Capex To Depreciation0.570.60270.6613
Pretty Stable
PB Ratio9.866.46112.3062
Slightly volatile
EV To Sales0.230.24573.0111
Slightly volatile
Inventory Turnover30.5933.809630.4866
Slightly volatile
Days Of Inventory On Hand11.0510.795712.2348
Slightly volatile
Payables Turnover12.0213.953914.3273
Pretty Stable
Sales General And Administrative To Revenue0.00130.00150.0016
Slightly volatile
Capex To Revenue0.00930.00960.0087
Slightly volatile
Cash Per Share0.620.66190.3516
Slightly volatile
Payout Ratio1.661.872.0381
Slightly volatile
Days Payables Outstanding28.3526.157525.9768
Very volatile
Intangibles To Total Assets0.120.12760.4575
Slightly volatile
Current Ratio2.462.1532.21
Slightly volatile
Receivables Turnover9.698.08149.8415
Slightly volatile
Shareholders Equity Per Share0.04540.04780.6987
Very volatile
Debt To Equity36.0334.31374.8738
Slightly volatile
Capex Per Share0.03250.05050.0252
Slightly volatile
Average Receivables12.8 M14.4 M15.7 M
Slightly volatile
Revenue Per Share2.695.24242.5155
Slightly volatile
Interest Debt Per Share1.831.7410.4402
Slightly volatile
Debt To Assets0.750.7130.2777
Slightly volatile
Graham Number0.220.260.2782
Slightly volatile
Operating Cycle45.555.96149.9993
Slightly volatile
Price Book Value Ratio9.866.46112.3062
Slightly volatile
Days Of Payables Outstanding28.3526.157525.9768
Very volatile
Dividend Payout Ratio1.661.872.0381
Slightly volatile
Ebt Per Ebit0.981.07560.9582
Pretty Stable
Company Equity Multiplier50.5348.1247.6766
Slightly volatile
Long Term Debt To Capitalization1.010.96290.3402
Slightly volatile
Total Debt To Capitalization1.020.97170.4008
Slightly volatile
Debt Equity Ratio36.0334.31374.8738
Slightly volatile
Quick Ratio2.261.96071.9396
Slightly volatile
Cash Ratio0.880.95120.5693
Slightly volatile
Cash Conversion Cycle24.8829.803524.5057
Slightly volatile
Days Of Inventory Outstanding11.0510.795712.2348
Slightly volatile
Days Of Sales Outstanding34.4445.165337.7638
Slightly volatile
Price To Book Ratio9.866.46112.3062
Slightly volatile
Fixed Asset Turnover9.9210.443673.4794
Slightly volatile
Debt Ratio0.750.7130.2777
Slightly volatile
Price Sales Ratio0.0560.05893.8364
Slightly volatile
Asset Turnover2.062.27782.3004
Slightly volatile
Gross Profit Margin0.210.13730.2136
Slightly volatile
Price Fair Value9.866.46112.3062
Slightly volatile

Oncology Institute Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap22 M23.2 M490.7 M
Slightly volatile
Enterprise Value91.8 M96.7 M502.6 M
Slightly volatile

Oncology Fundamental Market Drivers

Cash And Short Term Investments49.7 M

Oncology Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Oncology Institute Financial Statements

Investors use fundamental indicators, such as Oncology Institute's revenue or net income, to determine how well the company is positioned to perform in the future. Although Oncology Institute's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue4.7 M4.9 M
Total Revenue393.4 M256 M
Cost Of Revenue339.4 M208.9 M
Stock Based Compensation To Revenue 0.03  0.04 
Capex To Revenue 0.01  0.01 
Revenue Per Share 5.24  2.69 
Ebit Per Revenue(0.15)(0.16)

Currently Active Assets on Macroaxis

When determining whether Oncology Institute offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncology Institute's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncology Institute Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncology Institute Stock:
Check out the analysis of Oncology Institute Correlation against competitors.
For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.70)
Revenue Per Share
5.321
Quarterly Revenue Growth
0.103
Return On Assets
(0.18)
Return On Equity
(2.78)
The market value of Oncology Institute is measured differently than its book value, which is the value of Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Oncology Institute's value that differs from its market value or its book value, called intrinsic value, which is Oncology Institute's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncology Institute's market value can be influenced by many factors that don't directly affect Oncology Institute's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncology Institute's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.